The Future of Observational Epidemiology: Improving Data and Design to Align With Population Health.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 22 09 2018
revised: 29 01 2019
accepted: 30 01 2019
pubmed: 14 3 2019
medline: 11 2 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

Improvements in data resources and computational power provide important opportunities to ensure the continued relevance and growth of observational epidemiology. To achieve that promise, rigorous statistical analyses are important but not sufficient. We must prioritize articulating relevant research questions and developing strong study designs. Relevance depends on designing observational research so it delivers actionable clinical or population health evidence. Expanding data sources, including administrative records and data from emerging technologies such as sensors, can potentially be leveraged to improve study design, statistical power, measurement, and availability of evidence on diverse populations. With these advantages, particularly evidence on the heterogeneity of treatment effects, observational research can better guide design of randomized trials. Evidence on the heterogeneity of treatment effects is also essential to extend the evidence from randomized trials beyond the narrow range of settings and populations for which trials have been conducted. Machine learning tools will likely grow in importance in observational epidemiology in coming years, although we need careful attention to the appropriate uses of prediction models. Despite the potential of these innovations, they will only be useful if embedded in theoretical frameworks motivated by applied clinical and population health questions.

Identifiants

pubmed: 30865219
pii: 5379098
doi: 10.1093/aje/kwz030
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

836-839

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

M Maria Glymour (MM)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.

Kirsten Bibbins-Domingo (K)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Department of Medicine, University of California, San Francisco, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH